Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2017’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

The report reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics and enlists all their major and minor projects

The report assesses Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Aeglea BioTherapeutics Inc

Affimed GmbH

Altor BioScience Corp

Amgen Inc

ARA Healthcare Pvt Ltd

Ariad Pharmaceuticals Inc

Array BioPharma Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Autolus Ltd

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

Bio-Path Holdings Inc

BioSight Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Cantargia AB

Celgene Corp

Cellectis SA

Cellestia Biotech AG

Cellular Biomedicine Group Inc

Ceronco Biosciences

Cielo Therapeutics Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Enlivex Therapeutics Ltd

Epizyme Inc

Erytech Pharma SA

Fate Therapeutics Inc

Formula Pharmaceuticals Inc

Gamida Cell Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

iDD biotech SAS

Immunomedics Inc

Incyte Corp

Interprotein Corp

Jasco Pharmaceuticals LLC

Jazz Pharmaceuticals Plc

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kite Pharma Inc

Les Laboratoires Servier SAS

medac GmbH

Medivir AB

Merck & Co Inc

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

Molecular Templates Inc

MorphoSys AG

NantKwest Inc

NBE-Therapeutics AG

Nimbus Therapeutics LLC

Novartis AG

NovImmune SA

Omeros Corp

OncoTartis Inc

OncoTherapy Science Inc

OSE Immunotherapeutics

Pascal Biosciences Inc

Pfenex Inc

Pfizer Inc

Pharma Mar SA

Polyphor Ltd

Regeneron Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Seattle Genetics Inc

Sellas Life Sciences Group Ltd

Shire Plc

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Sun Pharma Advanced Research Company Ltd

SYNIMMUNE GmbH

Syros Pharmaceuticals Inc

Takara Bio Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Trillium Therapeutics Inc

Verastem Inc

Xbrane Biopharma AB

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview 8

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 38

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 56

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles 103

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 835

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 840

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 841

Appendix 855

List of Tables

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2017 32

Number of Products under Development by Companies, H2 2017 34

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 35

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 36

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 37

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 38

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 39

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 40

Number of Products under Development by Universities/Institutes, H2 2017 41

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 43

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 44

Products under Development by Companies, H2 2017 45

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 46

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 47

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 48

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 49

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 50

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 51

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 52

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 53

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 54

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 55

Products under Development by Universities/Institutes, H2 2017 56

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 58

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 60

Number of Products by Stage and Target, H2 2017 62

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 63

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 64

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 65

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 66

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 67

Number of Products by Stage and Mechanism of Action, H2 2017 69

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 70

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 71

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 72

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 73

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 74

Number of Products by Stage and Route of Administration, H2 2017 76

Number of Products by Stage and Molecule Type, H2 2017 78

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by 4SC AG, H2 2017 79

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AbbVie Inc, H2 2017 80

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Actinium Pharmaceuticals Inc, H2 2017 80

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ADC Therapeutics Sarl, H2 2017 81

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Aeglea BioTherapeutics Inc, H2 2017 81

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Affimed GmbH, H2 2017 82

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Altor BioScience Corp, H2 2017 82

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Amgen Inc, H2 2017 83

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ARA Healthcare Pvt Ltd, H2 2017 83

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ariad Pharmaceuticals Inc, H2 2017 83

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Array BioPharma Inc, H2 2017 84

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AstraZeneca Plc, H2 2017 84

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Atara Biotherapeutics Inc, H2 2017 85

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Autolus Ltd, H2 2017 85

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 86

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bexion Pharmaceuticals LLC, H2 2017 86

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bio-Path Holdings Inc, H2 2017 87

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by BioSight Ltd, H2 2017 87

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Boehringer Ingelheim GmbH, H2 2017 88

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bristol-Myers Squibb Co, H2 2017 88

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Calithera Biosciences Inc, H2 2017 89

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by CanBas Co Ltd, H2 2017 89

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cantargia AB, H2 2017 90

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Celgene Corp, H2 2017 90

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellectis SA, H2 2017 91

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellestia Biotech AG, H2 2017 91

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellular Biomedicine Group Inc, H2 2017 92

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ceronco Biosciences, H2 2017 92

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cielo Therapeutics Inc, H2 2017 92

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 93

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 93

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 94

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Eli Lilly and Co, H2 2017 94

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Enlivex Therapeutics Ltd, H2 2017 95

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Epizyme Inc, H2 2017 95

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Erytech Pharma SA, H2 2017 96

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Fate Therapeutics Inc, H2 2017 96

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Formula Pharmaceuticals Inc, H2 2017 97

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gamida Cell Ltd, H2 2017 97

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gilead Sciences Inc, H2 2017 98

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by GlaxoSmithKline Plc, H2 2017 98

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by iDD biotech SAS, H2 2017 99

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Immunomedics Inc, H2 2017 99

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Incyte Corp, H2 2017 100

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Interprotein Corp, H2 2017 100

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Jasco Pharmaceuticals LLC, H2 2017 101

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Jazz Pharmaceuticals Plc, H2 2017 101

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Johnson & Johnson, H2 2017 102

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Juno Therapeutics Inc, H2 2017 103

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Karyopharm Therapeutics Inc, H2 2017 103

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Kiadis Pharma NV, H2 2017 104

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Kite Pharma Inc, H2 2017 104

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Les Laboratoires Servier SAS, H2 2017 105

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by medac GmbH, H2 2017 105

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Medivir AB, H2 2017 106

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Merck & Co Inc, H2 2017 106

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 107

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Miltenyi Biotec GmbH, H2 2017 107

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Molecular Templates Inc, H2 2017 108

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by MorphoSys AG, H2 2017 108

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NantKwest Inc, H2 2017 109

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NBE-Therapeutics AG, H2 2017 109

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Nimbus Therapeutics LLC, H2 2017 109

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Novartis AG, H2 2017 110

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NovImmune SA, H2 2017 111

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Omeros Corp, H2 2017 111

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OncoTartis Inc, H2 2017 112

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OncoTherapy Science Inc, H2 2017 112

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OSE Immunotherapeutics, H2 2017 113

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pascal Biosciences Inc, H2 2017 113

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pfenex Inc, H2 2017 114

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pfizer Inc, H2 2017 114

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pharma Mar SA, H2 2017 115

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Polyphor Ltd, H2 2017 115

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 116

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sanofi, H2 2017 117

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sareum Holdings Plc, H2 2017 117

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Seattle Genetics Inc, H2 2017 118

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sellas Life Sciences Group Ltd, H2 2017 118

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Shire Plc, H2 2017 119

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sorrento Therapeutics Inc, H2 2017 119

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 120

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 120

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by SYNIMMUNE GmbH, H2 2017 121

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Syros Pharmaceuticals Inc, H2 2017 121

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Takara Bio Inc, H2 2017 122

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Tolero Pharmaceuticals Inc, H2 2017 122

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 123

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Trillium Therapeutics Inc, H2 2017 123

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Verastem Inc, H2 2017 124

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Xbrane Biopharma AB, H2 2017 124

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ZIOPHARM Oncology Inc, H2 2017 125

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2017 858

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2017 (Contd..1), H2 2017 859

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2017 (Contd..2), H2 2017 860

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2017 (Contd..3), H2 2017 861

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2017 (Contd..4), H2 2017 862

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products, H2 2017 863

List of Figures

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2017 32

Number of Products under Development by Companies, H2 2017 33

Number of Products under Development by Universities/Institutes, H2 2017 41

Number of Products by Top 10 Targets, H2 2017 61

Number of Products by Stage and Top 10 Targets, H2 2017 61

Number of Products by Top 10 Mechanism of Actions, H2 2017 68

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 68

Number of Products by Routes of Administration, H2 2017 75

Number of Products by Stage and Routes of Administration, H2 2017 75

Number of Products by Top 10 Molecule Types, H2 2017 77

Number of Products by Stage and Top 10 Molecule Types, H2 2017 77

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports